Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of a Novel Dual Orexin Receptor Antagonist in Patients With Sleep Disturbance and Hepatic Encephalopathy

NCT07830303 is registered in ClinicalTrials.gov with Wang Fengmei as lead sponsor.

NCT NCT07830303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07830303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of a Novel Dual Orexin Receptor Antagonist in Patients With Sleep Disturbance and Hepatic Encephalopathy
Lead sponsor
Wang Fengmei
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
February 28, 2029
Enrollment
180 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic encephalopathy, liver cirrhosis, sleep disturbance